Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (DE:8AT)
FRANKFURT:8AT
RESEARCH TOOLSreports
Holding DE:8AT?
Track your performance easily
8AT Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.60 - €2.45
Previous Close€2.4
Volume0.00
Average Volume (3M)4.86K
Market Cap
€172.08M
Enterprise Value€52.14M
Total Cash (Recent Filing)$127.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.02
Next Earnings
Feb 20, 2025EPS Estimate
-€0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,430,942
10 Day Avg. Volume2,347
30 Day Avg. Volume4,856
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.28
Price to Sales (P/S)6.75
Price to Cash Flow (P/CF)2.10
P/FCF Ratio2.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit3.96
Enterprise Value/Ebitda-0.91
Forecast
1Y Price Target
€2.35Price Target Upside0.80% Upside
Rating ConsensusHold
Number of Analyst Covering4
Aclaris Therapeutics News
PremiumCompany Announcements
Aclaris Therapeutics Reports Positive Q3 2024 Milestones
PremiumPre-Earnings
Is ACRS a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Financial StabilityACRS reported cash and equivalents of ~$173mn, which the company expects to fund operations into 2028.
Pipeline DevelopmentThe company initiated a Phase 2a open-label trial of oral ATI-2138 (ITK/JAK3 inhibitor) in moderate to severe atopic dermatitis (AD), indicating progress in its pipeline development.
Strategic PartnershipsACRS received a $26.5 million upfront payment and is eligible for up to $5 million in additional sales milestones from selling royalties and milestones from Olumiant sales.
Bears Say
Analyst RatingAnalyst reiterates Neutral rating without a price target, awaiting further clarity on the rest of the company's pipeline.
Clinical TrialsA company-wide strategic review was initiated following disappointing clinical data from zunsemetinib in rheumatoid arthritis and hidradenitis suppurativa, where both studies failed to achieve primary and key secondary endpoints.
Strategic PartnershipsFailure to establish a partnership to conduct further development of ATI-1777.
---
8AT FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was €0.59 and its highest was €2.45 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Currently, no data Available
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 98 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Nov 06, 2024. The company reported -€0.103 earnings per share for the quarter, missing the consensus estimate of -€0.006 by -€0.098.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -€0.13.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 71,430,940 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -€0.103 in its last earnings report, missing expectations of -€0.006. Following the earnings report the stock price went down -0.878%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Among the largest hedge funds holding Aclaris Therapeutics’s share is Aisling Capital Management LP. It holds Aclaris Therapeutics’s shares valued at 478K.
---
Aclaris Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
278.88%
12-Months-Change
Fundamentals
Return on Equity
-25.83%
Trailing 12-Months
Asset Growth
-16.47%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
---
8AT Company Deck
---
8AT Earnings Call
Q1 2024
0:00 / 0:00
---
8AT Stock 12 Month Forecast
Average Price Target
€2.35
▲(0.80% Upside)
Technical Analysis
Aclaris Therapeutics
―
AnaptysBio
―
Seres Therapeutics
―
Omeros
―
Pliant Therapeutics
―
---